PARP inhibitor prevented accumulation of cellular ADP-ribose and cell death upon H2O2 exposure in ARH3-deficient cells, suggesting that PARP is a therapeutic target for the ARH3-dependent neurodegenerative diseases. This evidence concerns the gene PARP1 and neurodegenerative disease.